Drug-eluting stent penetration
This article was originally published in The Gray Sheet
The decline in use of drug-eluting stents in the U.S. reached a new low in the fourth quarter of 2007 - 62% of all stent placements - according to a survey of 75 hospitals by consultant Goodroe Healthcare Solutions. That figure is down from an average of 78% in Q4 of 2006 based on last year's Goodroe survey, and 75% in January (1"The Gray Sheet" Jan. 22, 2007, p. 11). The share of Johnson & Johnson/Cordis' Cypher and Boston Scientific's Taxus DES compared with bare-metal stents has held steady since September, the data shows
You may also be interested in...
U.S. drug-eluting stent utilization rates markedly declined in the fourth quarter of 2006, most significantly in the last month of the year, as doctors chose to use bare-metal stents more frequently due to potential safety risks, a recent survey of about 65 hospitals suggests
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.